范可尼贫血中突变类型与染色体脆性的预后意义
西班牙范可尼贫血患者登记研究描述了227例患者最长30年的临床演变,数据提示50岁时累积癌症发生率为86%。染色体脆性较低者畸形谱较轻、血液学损害出现较晚、骨髓衰竭较轻且癌症风险较低;存在突变型FANCA蛋白表达者及FANCD2双等位基因突变者预后较好。
要点
- 227例患者随访长达30年,50岁时累积癌症发生率为86%。
- 染色体脆性较低者畸形谱较轻、血液学损害出现较晚、骨髓衰竭较轻且癌症风险较低。
- 存在突变型FANCA蛋白表达者预后优于缺乏该蛋白者,FANCD2双等位基因突变者预后优于FANCA和FANCG双等位基因突变者。
核心结论
- 染色体脆性与遗传低形态突变(genetic hypomorphism)对临床结局的影响提示突变型FA蛋白保留残余活性。
- 该发现应鼓励开发旨在部分或完全增强突变型FA功能的新型治疗策略,从而预防或延缓FA患者的骨髓衰竭和癌症。
研究设计与样本
- 西班牙范可尼贫血患者登记研究收集参与者的临床特征、染色体脆性、遗传亚型和DNA测序数据。
- 本文描述227例患者最长30年的临床演变。
- 临床试验注册号:NCT06490510。
主要发现
- 数据提示50岁时累积癌症发生率为86%。
- 染色体脆性较低的患者畸形谱较轻,且后期出现的血液学损害、骨髓衰竭严重程度和癌症风险方面的结局更好。
- 存在突变型FANCA蛋白表达(遗传低形态)的患者结局优于缺乏该蛋白的患者。
- FANCD2双等位基因突变(主要为低形态突变)患者预后一致优于FANCA和FANCG双等位基因突变患者,FANCG双等位基因突变患者缺乏突变蛋白与其较差结局相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fanconi anemia (FA) is a rare genetic disease characterized by high phenotypic and genotypic heterogeneity, and extreme chromosome fragility. To better understand the natural history of FA, identify genetic risk and prognostic factors, and develop novel therapeutic strategies, the Spanish Registry of Patients with FA collects data on clinical features, chromosome fragility, genetic subtypes, and DNA sequencing with informed consent of participating individuals. In this article, we describe the clinical evolution of 227 patients followed up for up to 30 years, for whom our data indicate a cumulative cancer incidence of 86% by age 50. We found that patients with lower chromosome fragility had a milder malformation spectrum and better outcomes in terms of later-onset hematologic impairment, less severe bone marrow failure, and lower cancer risk. We also found that outcomes were better for patients with mutations leading to mutant FANCA protein expression (genetic hypomorphism) than for patients lacking this protein. Likewise, prognosis was consistently better for patients with biallelic mutations in FANCD2 (mainly hypomorphic mutations) than for patients with biallelic mutations in FANCA and FANCG, with the lack of the mutant protein in patients with biallelic mutations in FANCG contributing to their poorer outcomes. Our results regarding the clinical impact of chromosome fragility and genetic hypomorphism suggest that mutant FA proteins retain residual activity. This finding should encourage the development of novel therapeutic strategies aimed at partially or fully enhancing mutant FA function, thereby preventing or delaying bone marrow failure and cancer in patients with FA. Clinical Trial Registration number: NCT06490510.
引用
- Ramírez MJ, Pujol R, Minguillón J, et al. Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. Am J Hematol. 2024. PMID: 39562502. doi:10.1002/ajh.27520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。